L&K Biomed Ltd. (KOSDAQ:156100)
South Korea
· Delayed Price · Currency is KRW 6,190.00
-120.00 (-1.90%)
At close: Mar 31, 2025, 3:30 PM KST
L&K Biomed Revenue
In the year 2024, L&K Biomed had annual revenue of 36.09B KRW with 20.69% growth. L&K Biomed had revenue of 10.02B in the quarter ending December 31, 2024, with 40.87% growth.
Revenue
36.09B
Revenue Growth
+20.69%
P/S Ratio
3.48
Revenue / Employee
601.54M
Employees
60
Market Cap
125.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 36.09B | 6.19B | 20.69% |
| Dec 31, 2023 | 29.90B | 10.14B | 51.28% |
| Dec 31, 2022 | 19.77B | 4.39B | 28.59% |
| Dec 31, 2021 | 15.37B | -3.98B | -20.58% |
| Dec 31, 2020 | 19.36B | -7.22B | -27.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Electronics | 300.87T |
| SK hynix | 66.19T |
| LG Energy Solution | 25.62T |
| Samsung Biologics | 4,547.32B |
| Hyundai Motor Company | 175.23T |
| Celltrion | 3,557.30B |
| Kia Corporation | 107.45T |
| KB Financial Group | 15.01T |